Publication

[Scientific Reports] Investigators confirmed that pinostilbene directly bound to androgen receptor and inhibited its activation and translocalization. Their results suggested that pinostilbene has the potential to treat enzalutamide-resistant CRPC.

[Scientific Reports] Scientists suggested that editing of miR-379 attenuated the growth-suppressive function of unedited miR-379 in androgen-sensitive prostate cancer cells, thereby promoting tumor growth.

[Toxicology and Applied Pharmacology] Researchers explored Lupeol's potential in enhancing the chemosensitivity of chemoresistant prostate cancer cells to Enzalutamide in vitro and in a mouse model.

[Molecular And Cellular Biochemistry] In vitro CRPC cell lines were used to determine the effect of YAP1 on glutamine uptake and metabolism to glutathione and RSL3-induced ferroptosis.

[The Prostate] In vitro/ex vivo analysis of erdafitinib and CH5183284 demonstrated robust and moderate growth suppression of androgen receptor-positive CRPC, respectively.

[PLOS One] Employing taxane-resistant DU145-TXR cells and a combination of cytotoxicity, apoptosis, and cell cycle assays, scientists' findings demonstrated that fatty acid binding protein 5 knockdown sensitized the cells to docetaxel.